BioAge Labs Past Earnings Performance
Past criteria checks 0/6
BioAge Labs's earnings have been declining at an average annual rate of -20.3%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually.
Key information
-20.3%
Earnings growth rate
-19.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -42.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
No updates
Revenue & Expenses Breakdown
How BioAge Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -62 | 15 | 36 |
| 31 Mar 24 | 0 | -66 | 15 | 35 |
| 31 Dec 23 | 0 | -64 | 15 | 34 |
Quality Earnings: Y7G is currently unprofitable.
Growing Profit Margin: Y7G is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if Y7G's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare Y7G's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: Y7G is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: Y7G has a negative Return on Equity (-42.66%), as it is currently unprofitable.